DANIEL L. KISNER - 13 Jun 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
13 Jun 2023
Net transactions value
-$40.03
Form type
4
Filing time
15 Jun 2023, 16:29:40 UTC
Previous filing
31 May 2023
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award $0 +47,824 +170% $0.000000 75,893 13 Jun 2023 Direct F1
transaction ZYNE Common Stock Sale $40.03 -115 -0.15% $0.3481 75,778 14 Jun 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYNE Stock Option (right to buy) Award $0 +71,736 $0.000000 71,736 13 Jun 2023 Common Stock 71,736 $0.3501 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock award vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F3 The option vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders.